Frontiers in Oncology (Oct 2022)

A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy

  • Dristhi Ragoonanan,
  • Saleh Bhar,
  • Gopi Mohan,
  • Fernando Beltramo,
  • Sajad J. Khazal,
  • Caitlin Hurley,
  • Clark Andersen,
  • Steven Margossian,
  • Sattva S. Neelapu,
  • Elizabeth Shpall,
  • Cristina Gutierrez,
  • Priti Tewari,
  • Basirat Shoberu,
  • Aimee Talleur,
  • David McCall,
  • Cesar Nunez,
  • Branko Cuglievan,
  • Francesco Paolo Tambaro,
  • Demetrios Petropoulos,
  • Hisham Abdel-Azim,
  • Kris M. Mahadeo

DOI
https://doi.org/10.3389/fonc.2022.1022901
Journal volume & issue
Vol. 12

Abstract

Read online

Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Reports of inequity and related disparities in care are emerging. In this multicenter study of ALL patients admitted for anti-leukemia therapy, who required pediatric intensive care (ICU) support (n = 205), patients receiving tisagenlecleucel (n = 39) were compared to those receiving conventional chemotherapy (n = 166). The median time to ICU transfer was 6 (0–43) versus 1 (0–116) days, respectively (p < 0.0001). There was no difference in the use of vasopressor, ionotropic, sedating, and/or paralytic agents between groups, but use of dexamethasone was higher among tisagenlecleucel patients. Patients receiving tisagenlecleucel were more likely to have cardiorespiratory toxicity (p = 0.0002), but there were no differences in diagnostic interventions between both groups and/or differences in ICU length of stay and/or overall hospital survival. Toxicities associated with tisagenlecleucel are generally reversible, and our findings suggest that resource utilization once admitted to the ICU may be similar among patients with ALL receiving tisagenlecleucel versus conventional chemotherapy. As centers consider improved access to care and the feasibility of tisagenlecleucel certification, our study may inform strategic planning.

Keywords